Dergiler / Medicine Science / 2016 / Cilt: 5 - Sayı: 1

Risk of Malignancy Index in the Pre-Operative Evaluation of Patients with Adnexal Masses

Sayfa
1–11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

RMI to be a valuable, reliable and applicable method in primary evaluation of patients with adnexal masses, and a usable method for referral of advanced neoplasia to a more complex healthcare unit

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The aim of this study is to evaluate use of RISK of MALIGNANCY INDEX (RMI) in primary evaluation of adnexal masses without clear evidence of malignancy, by combining serum CA 125 levels, USG score and menopausal status.
📊
Temel Bulgular & Veri:A total of 40 women aged 20 to 65 years with ultrasound diagnosed adnexal masses, and serum measurement of cancer-associated antigen CA-125 levels, were studied.
💡
Sonuç & Katkı:RMI to be a valuable, reliable and applicable method in primary evaluation of patients with adnexal masses, and a usable method for referral of advanced neoplasia to a more complex healthcare unit
🔬Tür:Araştırma Makalesi
📍Kapsam:2005 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

The aim of this study is to evaluate use of RISK of MALIGNANCY INDEX (RMI) in primary evaluation of adnexal masses without clear evidence of malignancy, by combining serum CA 125 levels, USG score and menopausal status. It is a cross sectional study conducted at Department of gynaec- oncology, Gujarat Cancer and Research Institute, Ahmedabad. A total of 40 women aged 20 to 65 years with ultrasound diagnosed adnexal masses, and serum measurement of cancer-associated antigen CA-125 levels, were studied. They all had surgical exploration (laparotomy) between May 2005 to July 2007 .The RMI was based on menopausal status, ultrasound morphology of adnexal masses and absolute level of serum CA-125. RMI cut-off of 200 was chosen. The various testing methods were evaluated for sensitivity, specificity, positive and negative predictive values. The best performance was with a RMI at a cut-off of 200 with a sensitivity of 66.66%, specificity of 63.15%, positive predictive value of 66.66% and negative predictive value of 65.15% to diagnose malignancy. When RMI was used, it is better in detecting benign tumour and malignant tumour rather than individual component. RMI to be a valuable, reliable and applicable method in primary evaluation of patients with adnexal masses, and a usable method for referral of advanced neoplasia to a more complex healthcare unit

🔖

Bu Makaleye Atıf Yap

NAGENDRA, K. R., VAİSHNAV, G., SONİ, A., DAVE, K. (2016). Risk of Malignancy Index in the Pre-Operative Evaluation of Patients with Adnexal Masses. Medicine Science, Cilt: 5 - Sayı: 1, 1–11. https://ajindex.com/articles/277515

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Odukogbe AA, Adebamowo CA, Ola B, Olayemi O, Oladokun A, Adewole IF, Omigbodun OA, Aimakhu CO, Okunlola MA, Fakulujo O, Oluyemi FA. Ovarian cancerin Ibadan: Characteristics and management. J Obstet Gynaecol. 2004;24(3):294- 7
  2. Gillis CR, Hole DJ, Still RM, Davis J, Kaye SB. Medical audit, cancer registration, and survival in ovarian cancer. Lancet. 1991;337(8741):611-2
  3. Finkler NJ, Benacerraf B, Lavin PT, Wojciechowski C, Knapp RC. Comparison of serum CA-125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol. 1988;72(4):659-64
  4. Vasilev SA, Schlaerth JB, Campeau J, Morrow CP. Serum CA-125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol. 1988;71(5):751-6
  5. Zanaboni F, Vergadoro F, Presti M, Gallotti,Lombardi F,Bolis G,Tumour antigen CA125 as a marker of ovarian epithelial carcinoma.Gynecol Oncol. 1987; 28(1): 61-7
  6. Zurawski VR, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, Bast RC Jr, Ritts RE Jr, Malkasian G. An initial analysis of preoperative of serum CA125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol. 1983;30(1):7-14
  7. Fures R,Bukovic D,Hodek B,Klaric B,Herman R,Grubisic G.Preoperative tumour marker CA125 levels in relation to epithelial ovarin cancer stage. Coll Antrpol. 1999;23(1):189-94
  8. Maggino T, Gadducci A, D'Addario V, Pecorelli S, Lissoni A, Stella M, Romagnolo C, Federghini M, Zucca S, Trio D, et al.Prospective multi centre study on CA125 in post menopausal pelvic masses. Gynaecol. 1994;54(2):117-23
  9. Requard CK, Mettler FA Jr, Wicks JD. Preoperative sonography of malignant ovarian neoplasm. Am J Roentgenol. 1981;137(1):79-82
  10. Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ. Performance of USG as second line test to13serum 125 in ovarian cancer. BTOG. 2000;107(2):165-9
  11. DiSantis DJ,Scatariage JC,Kemp G,Given FT,Hsiu JG,Cramer MS.A prospective evaluation of transvaginal sonography for detection of ovarian disease. Am J Roentgenol. 1993;161(1): 91-4
  12. Tingulstad S1, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, Nustad K.Evaluation of riskof malignancy index based on serum CA 125 ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. Br J Obstet Gynecol. 1996;103(8):826-31
  13. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, OnsrudM. The risk of malignancy index to evaluate potential ovarian cancers in l